Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer

作者：Kaira Kyoichi^*; Tomizawa Yoshio; Yoshino Reiko; Miura Yosuke; Yoshii Akihiro; Iwasaki Yasuki; Koga Yasuhiko; Ono Akihiro; Hisada Takeshi; Minato Koichi; Sato Koji; Kazama Toshifumi; Ishihara Shinichi; Kohyama Kenya; Fueki Naoto; Saito Ryusei; Sunaga Noriaki

来源：Lung Cancer, 2013, 82(1): 103-108.

DOI：10.1016/j.lungcan.2013.07.008

• Bevacizumab
• Lung cancer
• Non-squamous NSCLC
• Response rate
• S-1

Background: We conducted a phase II study to evaluate the efficacy and safety-of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). %26lt;br%26gt;Patients and methods: Chemotherapy-naive patients received S-1 plus cisplatin with bevacizumab. S-1 (80 mg/m(2)) was administered orally twice daily for 14 days, cisplatin (60 mg/m2) on day 1, and bevacizumab (15 mg/kg) on day 1 and every 3 weeks for 4-6 cycles. Patients with an objective response or stable disease received maintenance bevacizumab every 3 weeks until disease progression. %26lt;br%26gt;Results: Thirty patients were enrolled in this study. The median number of chemotherapy was four (range, 1-6 cycles), and the median number of bevacizumab alone was three (range, 1-31 cycles). The grade 3/4 toxicities were neutropaenia (23%), thrombocytopaenia (10%), febrile neutropaenia (3%), hypertension (17%), pneumonia (7%), and bowel perforation (3%). The objective response rate was 71% (95% CI, 55-88%) for a disease control rate of 100%. The median progression-free and overall survival times were 7.0 months and 20.0 months, respectively. %26lt;br%26gt;Conclusions: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-naive non-squamous NSCLC.

• 出版日期2013-10